一、实验准备
1.**菌株准备**：培养用于喂养的大肠杆菌OP50和用于RNAi的HT115菌株
1. **培养基制备**：配制NGM琼脂平板，根据需要添加抗生素或诱导剂
2. **线虫同步化**：使用次氯酸钠处理成年线虫获取卵，或通过时间限制产卵获得年龄同步的线虫群体

## 二、基因操作
1. **突变体构建**
   - 获取现有突变体菌株(daf-2、rsks-1)
   - 通过杂交产生双突变体(daf-2 rsks-1)
   - 通过PCR或测序验证突变体基因型

2. **RNA干扰系统建立**
   - 构建靶向目标基因(如cyc-2.1)的RNAi质粒
   - 转化到HT115细菌中
   - 制备RNAi喂养平板(含IPTG和抗生素)

3. **组织特异性RNAi菌株准备**
   - 使用肠道特异性(rde-1突变体背景下肠道恢复)或生殖系特异性RNAi敏感菌株

## 三、寿命分析实验
1. **实验组设置**
   - 野生型N2线虫(对照组)
   - 单突变体(daf-2、rsks-1)
   - 双突变体(daf-2 rsks-1)
   - RNAi处理组(空载体对照、目标基因RNAi)

2. **寿命测定**
   - 将L4期或年轻成虫转移到实验平板(每组30-100条)
   - 每2-3天转移到新鲜平板并计数存活线虫
   - 记录每天死亡数量直至全部死亡

## 四、分子机制分析
1. **蛋白质水平分析**
   - 收集不同基因型线虫样本
   - 提取总蛋白
   - 进行Western blot检测关键蛋白(如磷酸化AAK-2/AMPK)

2. **翻译组分析**
   - 线虫裂解物制备
   - 多聚核糖体分析：在蔗糖梯度上分离不同翻译状态的mRNA
   - RNA提取和测序分析差异翻译基因

3. **应激反应分析**
   - 使用荧光报告基因(如Phsp-6::GFP检测线粒体应激)
   - 荧光显微镜成像和定量分析

## 五、通路验证实验
1. **上下位分析**
   - 在关键调控基因突变背景下(如daf-16(mu86))测试寿命表型
   - 确定通路组分之间的依赖关系

2. **组织特异性实验**
   - 使用组织特异性启动子驱动关键基因表达
   - 在不同组织特异性RNAi系统中敲低目标基因

3. **药理学验证**
   - 使用特异性抑制剂(如靶向TOR的雷帕霉素)处理线虫
   - 测量寿命和分子标志物变化

## 六、数据分析
1. **寿命数据分析**
   - 生成Kaplan-Meier生存曲线
   - 使用log-rank检验比较不同组间差异
   - 计算平均和最大寿命变化

2. **分子数据整合分析**
   - 翻译组和转录组数据差异分析
   - 通路富集分析确定关键调控网络
   - 整合蛋白质和RNA数据构建调控模型

3. **结果验证**
   - 使用替代方法验证关键发现
   - 在不同实验条件下重复核心实验
   - 与已发表文献数据比较确认发现的可靠性

这种系统性的实验流程允许研究人员全面了解胰岛素/IGF-1和TOR信号通路如何协同调控线虫寿命，并揭示潜在的分子机制。

-----


### **1. Experimental Purpose**  
The seminar addresses the molecular mechanisms underlying lifespan extension by targeting insulin/IGF-1 and TOR signaling pathways in *C. elegans*. Key experiments, such as generating ==double mutants== (e.g., *daf-2 rsks-1*), aim to determine whether combined inhibition of these pathways synergistically enhances longevity. The design directly tests this by comparing survival curves of wild-type, single mutants, and double mutants, supported by RNAi knockdowns to validate gene-specific contributions (e.g., *cyc-2.1*). Repeating similar designs in subsequent figures (e.g., Figure 2) serves to confirm robustness, explore tissue-specific effects (e.g., intestinal vs. germline regulation), and refine mechanistic models, such as AMPK-mediated feedback loops.  


### **2. Model System**  
**Model**: *C. elegans* is used due to its short lifespan (~20 days), genetic tractability, and conserved aging pathways with humans (e.g., insulin/IGF-1 signaling). Its transparency and ease of manipulation enable high-throughput screens and live imaging.  
**Alternatives**:  
- **Drosophila**: Larger size but limited genetic homology.  
- **Mice**: Translatable to humans but costly and ethically complex.  
- **Yeast**: Simple but lacks tissue complexity.  
**Ethical Considerations**: Minimal ethical concerns compared to vertebrates, aligning with reductionist research principles.  


### **3. Measurement Approach**
**Techniques**:  
- **Quantitative**: Lifespan analysis, RNAi screens, polysomal profiling.  
- **Semi-quantitative**: Western blotting (e.g., phospho-AAK-2 levels), fluorescence microscopy (e.g., UPRmt reporters).  
**Rationale**: These methods balance throughput (RNAi) and precision (polysomal profiling) to identify translational changes. Technical replicates (e.g., multiple lifespan assays) and controls (empty vector RNAi) minimize variability.  
**Biases**: Confounding factors like bacterial food source or temperature are controlled, but genetic background differences (e.g., strain variations) could affect reproducibility.  


### **4. Group Setting**  
**Groups**:  
- **Controls**: Wild-type N2, empty vector RNAi.  
- **Treatments**: *daf-2*, *rsks-1*, *daf-2 rsks-1* mutants; tissue-specific RNAi (e.g., germline vs. intestine).  
**Variables Controlled**: Age, temperature, and bacterial diet. Negative controls include *daf-16* null mutants to validate DAF-16 dependency.  
**Replicates**: Typically 50–100 worms per group, sufficient for statistical power (e.g., ANOVA with Bonferroni correction). A modified design could include dose-response RNAi or positive controls (e.g., dietary restriction).  


### **5. Data Analysis & Presentation**  
**Processing**: Survival curves are plotted using Kaplan-Meier analysis. Polysomal profiling data are normalized to total mRNA, and differential translation is calculated via log2 ratios.  
**Statistics**: Parametric tests (e.g., t-tests) and non-parametric tests (Mantel-Cox) are applied, with p-values adjusted for multiple comparisons.  
**Presentation**: Clear visualizations (e.g., heatmaps, survival plots) avoid misleading scaling. Results are cross-validated using orthogonal methods (e.g., Western blotting for AMPK activation and UPRmt reporters).  


**Key Takeaways**:  
The study highlights the power of integrative approaches combining genetics, translational profiling, and tissue-specific manipulations to uncover conserved aging mechanisms. Future directions could explore cross-species translational regulation (e.g., FOXO homologs in mammals) and therapeutic targets for age-related diseases.